Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.
DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ.
DeGraff DJ, et al. Among authors: cookson ms.
PLoS One. 2012;7(5):e36669. doi: 10.1371/journal.pone.0036669. Epub 2012 May 10.
PLoS One. 2012.
PMID: 22590586
Free PMC article.
Clinical Trial.